HRP20171639T1 - ORALNI PRIPRAVCI DOZIRANJA S ODGOĐENIM OSLOBAĐANJEM KOJI SADRŽE AMORFNI CDDO-Me - Google Patents
ORALNI PRIPRAVCI DOZIRANJA S ODGOĐENIM OSLOBAĐANJEM KOJI SADRŽE AMORFNI CDDO-Me Download PDFInfo
- Publication number
- HRP20171639T1 HRP20171639T1 HRP20171639TT HRP20171639T HRP20171639T1 HR P20171639 T1 HRP20171639 T1 HR P20171639T1 HR P20171639T T HRP20171639T T HR P20171639TT HR P20171639 T HRP20171639 T HR P20171639T HR P20171639 T1 HRP20171639 T1 HR P20171639T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- solid dosage
- form according
- proportion
- methyl cellulose
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 9
- 230000003111 delayed effect Effects 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 claims 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical group C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 238000007496 glass forming Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007962 solid dispersion Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Kruti oblik doziranja naznačen time da sadrži (A) čestice koje sadrže amorfni bardoksolon metil i pomoćnu tvar koja tvori staklo pomiješanu s (B) česticama koje sadrže hidroksipropil metil celulozu.
2. Kruti oblik doziranja prema zahtjevu 1, naznačen time da su navedene čestice (A) kruta disperzija amorfnog bardoksolon metila u staklastoj matrici.
3. Kruti oblik doziranja prema zahtjevu 2, naznačen time da su navedene čestice (A) proizvod postupka koji obuhvaća sušenje raspršivanjem mješavine bardoksolon metila i kopolimera metakrilne kiseline.
4. Kruti oblik doziranja prema zahtjevu 3, naznačen time da navedeni postupak obuhvaća sušenje raspršivanjem smjese bardoksolon metila i kopolimera metakrilne kiseline u omjeru 4:6.
5. Kruti oblik doziranja prema zahtjevu 1, naznačen time da je udio hidroksipropil metil celuloze između 1% i 40% (m/m) od ukupne formulacije.
6. Kruti oblik doziranja prema zahtjevu 5, naznačen time da je udio hidroksipropil metil celuloze između 2% i 20% (m/m) od ukupne formulacije.
7. Kruti oblik doziranja prema zahtjevu 5, naznačen time da je udio hidroksipropil metil celuloze između 4% i 10% (m/m) od ukupne formulacije.
8. Kruti oblik doziranja prema zahtjevu 5, naznačen time da je udio hidroksipropil metil celuloze između 5% i 7.5% (m/m) od ukupne formulacije.
9. Kruti oblik doziranja prema zahtjevu 5, naznačen time da je udio hidroksipropil metil celuloze između 7% i 7.5% (m/m) od ukupne formulacije.
10. Kruti oblik doziranja prema zahtjevu 5, naznačen time da je udio hidroksipropil metil celuloze 7% (m/m) od ukupne formulacije.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15260809P | 2009-02-13 | 2009-02-13 | |
EP10704298.8A EP2395979B1 (en) | 2009-02-13 | 2010-02-12 | Delayed release, oral dosage compositions that contain amorphous cddo-me |
PCT/US2010/024127 WO2010093944A2 (en) | 2009-02-13 | 2010-02-12 | Delayed release, oral dosage compositions that contain amorphous cddo-me |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171639T1 true HRP20171639T1 (hr) | 2017-12-15 |
Family
ID=42335073
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171639TT HRP20171639T1 (hr) | 2009-02-13 | 2017-10-26 | ORALNI PRIPRAVCI DOZIRANJA S ODGOĐENIM OSLOBAĐANJEM KOJI SADRŽE AMORFNI CDDO-Me |
HRP20191092 HRP20191092T1 (hr) | 2009-02-13 | 2019-06-17 | Pripravci za oralno doziranje s odgođenim otpuštanjem koji sadrže amorfni cddo-me |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191092 HRP20191092T1 (hr) | 2009-02-13 | 2019-06-17 | Pripravci za oralno doziranje s odgođenim otpuštanjem koji sadrže amorfni cddo-me |
Country Status (29)
Country | Link |
---|---|
US (2) | US8747901B2 (hr) |
EP (2) | EP3254675B1 (hr) |
JP (1) | JP5775464B2 (hr) |
KR (2) | KR101483203B1 (hr) |
CN (2) | CN105232471A (hr) |
AU (1) | AU2010213594B2 (hr) |
BR (1) | BRPI1008023B8 (hr) |
CA (1) | CA2752048C (hr) |
CO (1) | CO6361904A2 (hr) |
CY (2) | CY1119595T1 (hr) |
DK (2) | DK2395979T3 (hr) |
EA (1) | EA023652B1 (hr) |
ES (2) | ES2646816T3 (hr) |
HK (1) | HK1220130A1 (hr) |
HR (2) | HRP20171639T1 (hr) |
HU (2) | HUE044005T2 (hr) |
IL (1) | IL214258A (hr) |
LT (2) | LT3254675T (hr) |
MX (1) | MX2011008344A (hr) |
MY (1) | MY173715A (hr) |
NO (1) | NO2395979T3 (hr) |
NZ (1) | NZ594488A (hr) |
PL (2) | PL2395979T3 (hr) |
PT (2) | PT3254675T (hr) |
SG (1) | SG173601A1 (hr) |
SI (2) | SI3254675T1 (hr) |
TR (1) | TR201909743T4 (hr) |
WO (1) | WO2010093944A2 (hr) |
ZA (1) | ZA201105630B (hr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
TW201216958A (en) | 2008-01-11 | 2012-05-01 | Reata Pharmaceuticals Inc | Synthetic triterpenoids and methods of use in the treatment of disease |
CA2721666C (en) | 2008-04-18 | 2017-05-23 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
KR101735807B1 (ko) | 2008-04-18 | 2017-05-15 | 리타 파마슈티컬스 잉크. | C-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제 |
MX2010011437A (es) | 2008-04-18 | 2010-12-20 | Reata Pharmaceuticals Inc | Moduladores antioxidantes de inflamacion: derivados del acido oleanolico con saturacion en el anillo c. |
TW201006474A (en) | 2008-04-18 | 2010-02-16 | Reata Pharmaceuticals Inc | Natural products including an anti-flammatory pharmacore and methods of use |
ES2449396T3 (es) | 2008-07-22 | 2014-03-19 | Trustees Of Dartmouth College | Cianoenonas monocíclicas y métodos de uso de las mismas |
EP3254675B1 (en) | 2009-02-13 | 2019-05-15 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous cddo-me |
ME03713B (me) | 2010-04-12 | 2021-01-20 | Reata Pharmaceuticals Inc | Bardoksolon meтil za lečenje gojaznosтi |
US8513436B2 (en) | 2010-12-17 | 2013-08-20 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
PT2683731T (pt) | 2011-03-11 | 2019-07-12 | Reata Pharmaceuticals Inc | Derivados de triterpenóides c4-monometil e os métodos de utilização dos mesmos |
CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
PL3444261T3 (pl) | 2012-04-27 | 2021-07-19 | Reata Pharmaceuticals, Inc. | Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
WO2014040060A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
IL285832B2 (en) | 2013-08-23 | 2024-01-01 | Reata Pharmaceuticals Inc | Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs |
EP3212195A4 (en) | 2014-10-31 | 2018-06-06 | The Regents of The University of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
NZ734292A (en) | 2015-02-12 | 2022-09-30 | Reata Pharmaceuticals Inc | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
AU2016326704B2 (en) | 2015-09-23 | 2021-01-28 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses |
CN110198718B (zh) | 2016-11-08 | 2023-01-10 | 里亚塔医药控股有限责任公司 | 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法 |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
US11427533B2 (en) | 2017-07-13 | 2022-08-30 | Pliva Hrvatska D.O.O. | Crystalline polymorphs of bardoxolone methyl |
CN112004529B (zh) | 2018-04-06 | 2023-08-08 | 比利时胶囊公司 | 包含聚[(甲基丙烯酸甲酯)-共-(甲基丙烯酸)]的低纵横比颗粒的喷雾干燥方法 |
KR20210032936A (ko) | 2018-06-15 | 2021-03-25 | 리아타 파마슈티컬즈, 아이엔씨. | Il-17 및 ror감마의 저해를 위한 피라졸 및 이미다졸 화합물 |
JPWO2020111089A1 (ja) | 2018-11-27 | 2021-10-14 | 協和キリン株式会社 | 医薬組成物 |
US20230255982A1 (en) | 2020-05-09 | 2023-08-17 | Reata Pharmaceuticals Holdings, LLC | Methods of treating covid-19 using bardoxolone methyl or analogs thereof |
AU2021397631A1 (en) | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
CN114558019A (zh) * | 2022-03-26 | 2022-05-31 | 中国科学院昆明动物研究所 | 一种Rab13基因抑制剂及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
JP2008110962A (ja) * | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
JP4315182B2 (ja) * | 2006-10-30 | 2009-08-19 | ミツミ電機株式会社 | カメラモジュール |
JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
TW201216958A (en) | 2008-01-11 | 2012-05-01 | Reata Pharmaceuticals Inc | Synthetic triterpenoids and methods of use in the treatment of disease |
EP3254675B1 (en) | 2009-02-13 | 2019-05-15 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous cddo-me |
-
2010
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en active Application Filing
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active IP Right Grant
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Application Discontinuation
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
-
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
-
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
-
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
-
2017
- 2017-10-26 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
-
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171639T1 (hr) | ORALNI PRIPRAVCI DOZIRANJA S ODGOĐENIM OSLOBAĐANJEM KOJI SADRŽE AMORFNI CDDO-Me | |
NZ603042A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
HRP20201902T1 (hr) | Pripravci protiv raka | |
WO2008053253A3 (en) | Inhaler devices and bespoke pharmaceutical compositions | |
HRP20211140T1 (hr) | Pripravci protiv raka | |
RS52793B (en) | PHARMACEUTICAL DOSAGE FORMS | |
RS54559B1 (en) | APIKSABAN FORMULATIONS | |
NZ611467A (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
AR057212A1 (es) | Composicion de liberacion prolongada del principio activo, su proceso de preparacion y su utilizacion | |
MY159630A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
WO2013183062A3 (en) | Palatable formulations of ibuprofen | |
AR082566A1 (es) | Formulaciones liquidas de st-246 y metodos relacionados, proceso | |
CO6620043A2 (es) | Procedimiento de preparación de composiciones famacéuticas destinadas a la administración por vía oral que comprende uno o varios principios activos y las composiciones que las comprenden | |
SG196810A1 (en) | Controlled release pharmaceutical or foodformulation and process for its preparation | |
HRP20201386T1 (hr) | Farmaceutska kompozicija, koja sadrži čestice vezivnog sredstva za fosfat | |
NZ602442A (en) | A fast dissolving pharmaceutical composition | |
HRP20161340T1 (hr) | Formulacije darunavira | |
RS53554B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 2-OXO-1-PYROLIDINE DERIVATIVES | |
WO2011087629A3 (en) | Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients | |
MX2008001645A (es) | Composiciones de fexofendina en suspension farmaceutica oral. | |
HRP20200642T1 (hr) | Čvrsti obrazac za doziranje koji sadrži mikronizirani citizin | |
WO2010111264A3 (en) | Rasagiline formulations | |
HRP20141134T1 (hr) | Kruta farmaceutska formulacija | |
WO2013057741A3 (en) | Pharmaceutical compositions of ursodeoxycholic acid | |
BR112014029734A2 (pt) | materiais comestíveis e fabricação dos mesmos |